Marinus J. Van Oers

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine
Published: May 10, 2023

Prognosis of IGLV3-21R110 chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis.

Prognosis of IGLV3-21R110 chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis.

Journal: Leukemia
Published: November 29, 2022

Professor Anton Hagenbeek 1948-2021: Father of MRD and lymphoma expert.

Professor Anton Hagenbeek 1948-2021: Father of MRD and lymphoma expert.

Journal: Bone marrow transplantation
Published: May 18, 2021

Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.

Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.

Journal: Experimental hematology
Published: June 10, 2020

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study.

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study.

Journal: Blood cancer journal
Published: July 10, 2019

Saposin C is a frequent target of paraproteins in Gaucher disease-associated MGUS/multiple myeloma.

Saposin C is a frequent target of paraproteins in Gaucher disease-associated MGUS/multiple myeloma.

Journal: British journal of haematology
Published: July 26, 2018

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Journal: Haematologica
Published: March 28, 2018

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

Journal: Leukemia
Published: March 07, 2018

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma
Published: March 11, 2017

Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.

Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.

Journal: European journal of cancer (Oxford, England : 1990)
Published: September 25, 2016

The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.

The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma
Published: August 04, 2016

Analysis of prognosis in CLL: collaboration makes the difference.

Analysis of prognosis in CLL: collaboration makes the difference.

Journal: The Lancet. Oncology
Published: March 28, 2016
Showing 1-12 of 35

Last Updated: 09/26/2026